GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
GRAIL, Inc.NASDAQ: GRAL
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash growth accelerates
Q2 FY2026 net change in cash of $13.7M (cash outflow) rose 111.8% year over year, ahead of the -91.8% change in trailing-twelve-month net change in cash. Sequentially, it fell 92.4% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.
Context
- Net change in cash amounted to 26.6% of revenue in FY2025, down 65.8 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +111.8% holds above the trailing-twelve-month pace of -91.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 39.12M USD
- Year-over-year change
- -66.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.12M | -66.3% |
| FY2024 | 2024-12-31 | 116.07M | +180.3% |
| FY2023 | 2023-12-31 | (144.62M) | -818.3% |
| FY2022 | 2022-12-31 | 20.13M | +114.1% |
| FY2021 | 2021-12-31 | (143.19M) | — |
Net Change in Cash vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's LTM Jun 2026 net change in cash of $68.16M is the 4th largest of the 10 companies compared; the peer median is $2.59M.
- Its year-over-year change of -91.8% is the 5th highest of 9, against a peer median of -92.9%.
- Net change in cash amounts to 41.2% of revenue for GRAL, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $456.49M | +39698.6% | -26.3% | 35.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $359.67M | — | — | 90.5% |
| LTM Jun 2026 | $91.48M | -55.0% | -30.1% | 3.4% | |
| LTM Jun 2026 | $68.16M | -91.8% | +24.8% | 41.2% | |
| LTM Mar 2026 | $43.88M | -444.5% | -61.3% | 13.7% | |
| LTM Mar 2026 | $25.93M | -484.6% | -75.7% | 7.6% | |
| LTM Mar 2026 | $25M | +643.5% | — | 3.0% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $13.8M | -176.5% | — | 3.0% |
| LTM Jun 2026 | $9.18M | -95.4% | +56.9% | 1.2% | |
| LTM Mar 2026 | $2.59M | -90.4% | — | 4.0% | |
| Peer median (excluding GRAL) | $2.59M | -92.9% | -30.1% | 4.0% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.25B) | (5.4B) | (1.47B) | (2.03B) | (408.35M) |
| Depreciation & Amortization | 58.45M | 154.76M | 158.7M | 158.06M | 156.34M |
| Deferred Income Tax | 0 | (39.06M) | (38.15M) | (134.25M) | (126.15M) |
| Stock-Based Compensation | 681.91M | 75.73M | 97.24M | 86.08M | 58.28M |
| Change in Working Capital | 21.59M | (14.46M) | 7.72M | (24.28M) | 12.41M |
| Accounts Receivables | (6.88M) | (8.68M) | (1.38M) | (3.37M) | 1.69M |
| Inventory | (5.67M) | (14.08M) | (1.94M) | 3.07M | 2.62M |
| Accounts Payables | 1.3M | 2.34M | 2.89M | (14.64M) | (2.73M) |
| Other Working Capital | 32.85M | 5.95M | 8.16M | (9.35M) | 10.84M |
| Other Non-Cash Items | (201M) | 4.66B | 644.39M | 1.36B | 8.46M |
| Operating Cash Flow | (688.13M) | (561.31M) | (595.8M) | (577.16M) | (299.01M) |
| Capital Expenditures | (69.93M) | (22.86M) | (12.89M) | (5.21M) | (909K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (545.8M) | (1.31B) |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.22B |
| Other Investing Activities | 414.74M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 344.81M | (22.86M) | (12.89M) | (551.01M) | (85.05M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.98M | 0 | 0 | 0 | 423.32M |
| Common Stock Repurchased | (170K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 388.93M | 604.82M | 463.77M | 1.24B | 0 |
| Financing Cash Flow | 394.74M | 604.82M | 463.77M | 1.24B | 423.32M |
| Effect of Forex Changes | (194.61M) | (511K) | 305K | (62K) | (147K) |
| Net Change in Cash | (143.19M) | 20.13M | (144.62M) | 116.07M | 39.12M |
| Free Cash Flow | (758.06M) | (584.17M) | (608.69M) | (582.36M) | (299.01M) |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.